Improving indoor air quality for heart patients
Developing and Evaluating an Indoor Air Pollution Intervention Among Cardiovascular Patients: the AIRWISE Study
This study is testing a program to see if improving indoor air quality helps heart patients feel better after their procedures.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 20 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | University of Montana Academic / other |
| Locations | 1 site (Missoula, Montana) |
| Trial ID | NCT06384625 on ClinicalTrials.gov |
What this trial studies
This pilot study evaluates an intervention aimed at improving indoor air quality for patients who have recently undergone percutaneous coronary interventions. The AIRWISE program includes air filtration, education, and behavioral recommendations to enhance participants' awareness of air pollution. With 20 participants, the study focuses on assessing the acceptance and use of these intervention components, which will inform a larger NIH proposal for a randomized trial. The central hypothesis is that educational strategies and visual cues will increase knowledge about air pollution and improve compliance with the intervention.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older who have recently undergone a percutaneous coronary intervention at the Providence Heart Institute.
Not a fit: Patients who currently smoke or live with smokers, or those using high-efficiency air filtration systems, may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could lead to better health outcomes for cardiovascular patients by reducing their exposure to indoor air pollution.
How similar studies have performed: While this approach is innovative, similar studies focusing on air quality interventions for health improvement have shown promise, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult of at least 20 years of age * Undergone a percutaneous coronary intervention (PCI) procedure at the Providence Heart Institute (PHI). * One primary residence (5+ days per week) * Own a computer or electronic device (tablet or phone with web browser), and reliable internet connection or cell phone service (required to submit study surveys) * Access to a working email address (required to submit study surveys) * Electricity in the home (required to power the study equipment) Exclusion Criteria: * Current smoking of any kind (tobacco, cannabis, vape pens, cigars, etc.) or living in a household with someone who currently smokes * Current use of stand-alone home high efficiency purified air (HEPA) filtration or PAC unit in the home * Intention to move in the next 6 months * Another person in the household is enrolled in this study (one person per household can enroll) * Having any health condition that prevents the participants from having blood pressure measured using an upper-arm cuff: lymphedema, paresis or paralysis, arterial or venous lines/catheters, dialysis shunt, recent surgical wounds, or mastectomy
Where this trial is running
Missoula, Montana
- University of Montana — Missoula, Montana, United States (Recruiting)
Study contacts
- Study coordinator: Ethan S Walker, PhD
- Email: ethan.walker@umontana.edu
- Phone: 406-243-2063
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.